Combined lysosomal protein transmembrane 4 beta-35 and argininosuccinate synthetase expression predicts clinical outcome in hepatocellular carcinoma patients

Surgery Today

Volumn 41, Issue 6, 2011, Pages 810-817

  Yang, Hua ^a   Lin, Ming ^a   Xiong, Fuxia ^a   Yang, Yu ^a   Nie, Xiu ^b   McNutt, Michael A ^a   Zhou, Rouli ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Argininosuccinate synthetase; Hepatocellular carcinoma; Immunohistochemistry; Lysosomal protein transmembrane 4 beta; Prognosis

Indexed keywords

ALPHA FETOPROTEIN; ARGININOSUCCINATE SYNTHASE; LYSOSOMAL PROTEIN TRANSMEMBRANE 4 BETA 35; MEMBRANE PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER STAGING; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DISEASE MARKER; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MALE; METASTASIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTION; PROGNOSIS; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; TUMOR GROWTH; TUMOR VOLUME;

ADULT; AGED; ARGININOSUCCINATE SYNTHASE; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; ONCOGENE PROTEINS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 79960295674     PISSN: 09411291     EISSN: 14362813     Source Type: Journal    
DOI: 10.1007/s00595-010-4338-5     Document Type: Article

References (26)

1. D.M. Parkin F. Bray J. Ferlay P. Pisani 2005 Global cancer statistics, 2002 CA Cancer J Clin 55 74 108 15761078 10.3322/canjclin.55.2.74 (Pubitemid 40372904)
2. H.B. El-Serag A.C. Mason C. Key 2001 Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States Hepatology 33 62 75 11124821 10.1053/jhep.2001.21041 1:STN:280:DC%2BD3M%2FpvFShsw%3D%3D (Pubitemid 32016888)
3. G.W. Vainer E. Pikarsky Y. Ben-Neriah 2008 Contradictory functions of NF-kappaB in liver physiology and cancer Cancer Lett 267 182 188 18479806 10.1016/j.canlet.2008.03.016 1:CAS:528:DC%2BD1cXovF2hsLo%3D
4. E.C. Douglass 1997 Hepatic malignancies in childhood and adolescence (hepatoblastoma, hepatocellular carcinoma, and embryonal sarcoma) Cancer Treat Res 92 201 212 9494762 1:STN:280:DyaK1c7lsFyltA%3D%3D
5. G.Z. Shao R.L. Zhou Q.Y. Zhang Y. Zhang J.J. Liu J.A. Rui, et al. 2003 Molecular cloning and characterization of LAPTM4B, a novel gene upregulated in hepatocellular carcinoma Oncogene 22 5060 5069 12902989 10.1038/sj.onc.1206832 1:CAS:528:DC%2BD3sXmtVemsb4%3D (Pubitemid 37026404)
6. C. Peng R.L. Zhou G.Z. Shao J.A. Rui S.B. Wang M. Lin, et al. 2005 Expression of lysosome-associated protein transmembrane 4B-35 in cancer and its correlation with the differentiation status of hepatocellular carcinoma World J Gastroenterol 11 2704 2708 15884107 1:CAS:528:DC%2BD2MXlslKit7g%3D (Pubitemid 40704233)
7. H. Yang F.X. Xiong M. Lin Y. Yang X. Nie R.L. Zhou 2010 LAPTM 4B-35 overexpression is a risk factor for tumor recurrence and poor prognosis in hepatocellular carcinoma J Cancer Res Clin Oncol 136 275 281 19690886 10.1007/s00432-009-0659-4 1:CAS:528:DC%2BC3cXjtlaitg%3D%3D
8. X. Liu F. Xiong X. Wei H. Yang R. Zhou 2009 LAPTM4B-35, a novel tetratransmembrane protein and its PPRP motif play critical roles in proliferation and metastatic potential of hepatocellular carcinoma cells Cancer Sci 100 2335 2340 19843073 10.1111/j.1349-7006.2009.01346.x 1:CAS:528: DC%2BD1MXhsFOltrjJ
9. T. Ito K. Shiraki K. Sekoguchi T. Yamanaka K. Sugimoto K. Takase, et al. 2000 Hepatocellular carcinoma associated with adult-type citrullinemia Dig Dis Sci 45 2203 2206 11215740 10.1023/A:1026439913915 1:STN:280: DC%2BD3M7jsFWgsQ%3D%3D (Pubitemid 32060393)
10. B.J. Dillon V.G. Prieto S.A. Curley C.M. Ensor F.W. Holtsberg J.S. Bomalaski, et al. 2004 Incidence and distribution of argininosuccinate synthetase deficiency in human cancers: a method for identifying cancers sensitive to arginine deprivation Cancer 100 826 833 14770441 10.1002/cncr.20057 1:CAS:528:DC%2BD2cXhvF2qtbY%3D (Pubitemid 38176863)
11. K. Miyazaki H. Takaku M. Umeda T. Fujita W.D. Huang T. Kimura, et al. 1990 Potent growth inhibition of human tumor cells in culture by arginine deiminase purified from a culture medium of a Mycoplasma-infected cell line Cancer Res 50 4522 4527 2164440 1:CAS:528:DyaK3cXltVyru7w%3D (Pubitemid 20230386)
12. D.N. Wheatley E. Campbell 2003 Arginine deprivation, growth inhibition and tumour cell death: 3. Deficient utilisation of citrulline by malignant cells Br J Cancer 89 573 576 12888832 10.1038/sj.bjc.6601134 1:CAS:528: DC%2BD3sXlsl2rsb0%3D (Pubitemid 37026445)
13. W. Grabon 2006 Arginine as a crucial amino acid in carcinogenesis and tumor growth Postepy Hig Med Dosw (Online) 60 483 489
14. Y. Yang H. Yang M.A. McNutt F. Xiong X. Nie L. Li, et al. 2008 LAPTM4B overexpression is an independent prognostic marker in ovarian carcinoma Oncol Rep 20 1077 1083 18949404
15. S.M. Morris Jr. 2002 Regulation of enzymes of the urea cycle and arginine metabolism Annu Rev Nutr 22 87 105 12055339 10.1146/annurev.nutr.22.110801. 140547 1:CAS:528:DC%2BD38XmtF2ht7k%3D (Pubitemid 35221455)
16. G. Wu S.M. Morris Jr. 1998 Arginine metabolism: nitric oxide and beyond Biochem J 336 Pt1 1 17 9806879 1:CAS:528:DyaK1cXotVGltrs%3D (Pubitemid 28532555)
17. A. Husson C. Brasse-Lagnel A. Fairand S. Renouf A. Lavoinne 2003 Argininosuccinate synthetase from the urea cycle to the citrulline-NO cycle Eur J Biochem 270 1887 1899 12709047 10.1046/j.1432-1033.2003.03559.x 1:CAS:528:DC%2BD3sXjslGms78%3D (Pubitemid 36560809)
18. C.M. Ensor F.W. Holtsberg J.S. Bomalaski M.A. Clark 2002 Pegylated arginine deiminase (ADI-SS PEG20 000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo Cancer Res 62 5443 5450 12359751 1:CAS:528:DC%2BD38Xnsl2ls7s%3D
19. C.Y. Yoon Y.J. Shim E.H. Kim J.H. Lee N.H. Won J.H. Kim, et al. 2007 Renal cell carcinoma does not express argininosuccinate synthetase and is highly sensitive to arginine deprivation via arginine deiminase Int J Cancer 120 897 905 17096330 10.1002/ijc.22322 1:CAS:528:DC%2BD2sXht1elt7g%3D (Pubitemid 46175413)
20. K. Sugimura T. Ohno T. Kusuyama I. Azuma 1992 High sensitivity of human melanoma cell lines to the growth inhibitory activity of mycoplasmal arginine deiminase in vitro Melanoma Res 2 191 196 1450673 10.1097/00008390-199209000- 00007 1:CAS:528:DyaK3sXhtl2gtrk%3D
21. L. Scott J. Lamb S. Smith D.N. Wheatley 2000 Single amino acid (arginine) deprivation: rapid and selective death of cultured transformed and malignant cells Br J Cancer 83 800 810 10952786 10.1054/bjoc.2000.1353 1:CAS:528:DC%2BD3cXntFOhsLw%3D
22. D.N. Wheatley E. Campbell 2002 Arginine catabolism, liver extracts and cancer Pathol Oncol Res 8 18 25 11994758 10.1007/BF03033696 1:CAS:528: DC%2BD38Xos1Ciur4%3D (Pubitemid 34532775)
23. L. Feun M. You C.J. Wu M.T. Kuo M. Wangpaichitr S. Spector, et al. 2008 Arginine deprivation as a targeted therapy for cancer Curr Pharm Des 14 1049 1057 18473854 10.2174/138161208784246199 1:CAS:528:DC%2BD1cXmslKku7Y%3D (Pubitemid 351982554)
24. P.N. Cheng T.L. Lam W.M. Lam S.M. Tsui A.W. Cheng W.H. Lo, et al. 2007 Pegylated recombinant human arginase (rhArg-peg5 000 mw) inhibits the in vitro and in vivo proliferation of human hepatocellular carcinoma through arginine depletion Cancer Res 67 309 317 17210712 10.1158/0008-5472.CAN-06-1945 1:CAS:528:DC%2BD2sXisFSksQ%3D%3D (Pubitemid 46142789)
25. F. Izzo M. Montella A.P. Orlando G. Nasti G. Beneduce G. Castello, et al. 2007 Pegylated arginine deiminase lowers hepatitis C viral titers and inhibits nitric oxide synthesis J Gastroenterol Hepatol 22 86 91 17201887 10.1111/j.1440-1746.2006.04463.x 1:CAS:528:DC%2BD2sXitV2jtLY%3D (Pubitemid 44953422)
26. L.X. Qin Z.Y. Tang 2004 Recent progress in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma: a review of the literature J Cancer Res Clin Oncol 130 497 513 15205947 10.1007/s00432-004-0572- 9 1:CAS:528:DC%2BD2cXmt1Krtb0%3D